Investigating the role of METTL3 in aggressive chronic lymphocytic leukemia
Official title: Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
Funded at Beckman Research Institute/city of Hope · NIH-10880367 · Data updated 2026-11-12
This study is looking at how a protein called METTL3 affects aggressive chronic lymphocytic leukemia (CLL) and is testing new treatments that could help patients by targeting this protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $608,892 |
| NIH project number | 5R01CA282450-02 |
| Project ID | NIH-10880367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with aggressive chronic lymphocytic leukemia who may benefit from novel treatment approaches.
✕Less likely to help
Patients with indolent forms of chronic lymphocytic leukemia or those not diagnosed with CLL may not receive benefit from this research.
What this research studies
This research focuses on understanding how the METTL3 protein contributes to the development and progression of aggressive chronic lymphocytic leukemia (CLL). By analyzing the RNA and protein changes in CLL cells, the researchers aim to uncover the mechanisms by which METTL3 influences cancer behavior. The study also explores the potential of small molecule inhibitors targeting METTL3 as a new treatment option for patients with CLL. If successful, this research could lead to more effective therapies tailored to the biology of aggressive CLL.
Why it matters
Potential benefit: If successful, this research could provide new targeted therapies for patients with aggressive chronic lymphocytic leukemia.
How similar studies have gone: Other research has shown promising results with similar approaches targeting RNA splicing in hematological malignancies, indicating potential for success in this area.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wang, Lili — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Lili
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.